Clinical Trial Update: Effects of Immulina TM Supplements With PASC Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ImmulinaTM supplements in patients with Post-acute sequelae of SARS-CoV-2 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Immulina TM supplement

Snippet

Sponsor: University of Mississippi Medical Center | Conditions: Post Acute COVID-19 Syndrome | Phase 3 | Status: COMPLETED